The Zacks Analyst Blog Highlights: Bristol-Myers Squibb, Sanofi, AbbVie,
Celgene and Telus
CHICAGO, May 7, 2013
CHICAGO, May 7, 2013 /PRNewswire/ --Zacks.com announces the list of stocks
featured in the Analyst Blog. Every day the Zacks Equity Research analysts
discuss the latest news and events impacting stocks and the financial markets.
Stocks recently featured in the blog include Bristol-Myers Squibb Company
(NYSE:BMY), Sanofi (NYSE:SNY), AbbVie (NYSE:ABBV), Celgene Corporation
(Nasdaq:CELG) and Telus Corporation (NYSE:TU).
Get the most recent insight from Zacks Equity Research with the free Profit
from the Pros newsletter: http://at.zacks.com/?id=5513
Here are highlights from Monday's Analyst Blog:
Good News for Bristol-Myers
Bristol-Myers Squibb Company (NYSE:BMY) recently received positive news from
the US Food and Drug Administration (FDA) when the US regulatory authority
approved the pharma major's HIV drug Sustiva for treating children between
three months and three years. The body weight of the children should not
exceed 3.5 kilograms.
The approval provides a once-daily option as part of a regimen for HIV
infected children between three months and three years. Moreover, the "capsule
sprinkle" administration procedure is beneficial for children who cannot
swallow capsules or tablets.
We note that Sustiva is already approved for treating HIV infected patients
aged three years and above and weighing not less than 10 kilograms. The FDA
decision has expanded the patient population for Sustiva. This will boost the
drug's sales potential.
The FDA decided to expand the patient population for Sustiva on the basis of
data from three open-label studies, which evaluated the pharmacokinetics,
safety and antiretroviral activity of the drug combined with other
antiretroviral agents in 182 antiretroviral-naïve and – experienced patients
infected with HIV. The studies evaluated patients aged between three months
and 21 years for a median of 123 weeks.
The FDA's decision to broaden Sustiva's target population is encouraging for
Bristol-Myers, which has entered a challenging phase following the
genericization of Plavix. Plavix, co-developed with Sanofi (NYSE:SNY), went
off patent in the US in May 2012. The drug's genericization has resulted in
the loss of significant revenues for Bristol-Myers.
Bristol-Myers is looking to combat the challenges confronting it through
partnering deals and acquisitions and introducing new products to augment its
Bristol-Myers, a large cap pharma stock, carries a Zacks Rank # 3 (Hold).
AbbVie (NYSE:ABBV) appears to be more favorably placed in the large cap pharma
space with a Zacks Rank # 2 (Buy). Meanwhile, Celgene Corporation
(Nasdaq:CELG) too carries a Zacks Rank #2.
Telus Likely to Top Earnings
We expect Canada-based Telus Corporation (NYSE:TU), to beat expectations when
it reports its first-quarter 2013 results on May 9, 2013.
Why a Likely Positive Surprise?
Our proven model shows that Telus is likely to beat earnings because it has
the right combination of two key ingredients.Positive Zacks ESP
: Expected Surprise Prediction or ESP (Read: Zacks Earnings ESP: A Better
Method), which represents the difference between the Most Accurate estimate
and the Zacks Consensus Estimate, is +3.77%. This is a meaningful and leading
indicator of a likely positive earnings surprise.
Zacks Rank #3 (Hold): Telus currently has a Zacks Rank #3. Note that the
stocks with a Zacks Rank #1 (Strong Buy), 2 (Buy) and 3 (Hold) have a
significantly higher chance of beating the earnings.
The combination of Telus's Zacks Rank #3 (Hold) and +3.77% ESP makes us
confident of a positive earnings beat on May 9, 2013.
What is Driving the Better-Than-Expected Earnings?
Telus' ongoing investment in the expansion of its fiber optic network provides
compelling home entertainment services in the Western Canadian market. The
company continues to add new features as well as upgrading the existing
features of its popular Optik TV and Optik High Speed Internet broadband
services that are gaining strong traction across the Canadian region.
The company is providing 4G LTE networks with the popular smartphones, which
resulted in solid growth in its post-paid divisions.
However, Telus remains challenged by the weak Canadian economy and domestic
competition, which is expected to intensify with the entry of new wireless
players. Moreover, higher burden of subsidy cost associated with smartphones
coupled with lack of spectrum will continue to impede the company's growth
Want more from Zacks Equity Research? Subscribe to the free Profit from the
Pros newsletter: http://at.zacks.com/?id=5515.
About Zacks Equity Research
Zacks Equity Research provides the best of quantitative and qualitative
analysis to help investors know what stocks to buy and which to sell for the
Continuous coverage is provided for a universe of 1,150 publicly traded
stocks. Our analysts are organized by industry which gives them keen insights
to developments that affect company profits and stock performance.
Recommendations and target prices are six-month time horizons.
Zacks "Profit from the Pros" e-mail newsletter provides highlights of the
latest analysis from Zacks Equity Research. Subscribe to this free newsletter
Zacks.com is a property of Zacks Investment Research, Inc., which was formed
in 1978 by Leon Zacks. As a PhD from MIT Len knew he could find patterns in
stock market data that would lead to superior investment results. Amongst his
many accomplishments was the formation of his proprietary stock picking
system; the Zacks Rank, which continues to outperform the market by nearly a 3
to 1 margin. The best way to unlock the profitable stock recommendations and
market insights of Zacks Investment Research is through our free daily email
newsletter; Profit from the Pros. In short, it's your steady flow of
Profitable ideas GUARANTEED to be worth your time! Register for your free
subscription to Profit from the Pros at http://at.zacks.com/?id=5518.
Visit http://www.zacks.com/performance for information about the performance
numbers displayed in this press release.
Follow us on Twitter: http://twitter.com/zacksresearch
Join us on Facebook:
Disclaimer: Past performance does not guarantee future results. Investors
should always research companies and securities before making any investments.
Nothing herein should be construed as an offer or solicitation to buy or sell
Zacks Investment Research
800-767-3771 ext. 9339
SOURCE Zacks Investment Research, Inc.
Press spacebar to pause and continue. Press esc to stop.